Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of **inositol** (specifically myo-inositol) and **alpha-lactalbumin** is an oral formulation primarily investigated as a dietary supplement for **improving insulin resistance and reproductive/metabolic disturbances in women with polycystic ovary syndrome (PCOS)**, as well as **reducing insulin resistance and excessive fetal growth in gestational diabetes mellitus (GDM)**[1][3][4][5]. - Myo-inositol is a carbocyclic sugar involved in cellular signaling and metabolic regulation, known to improve insulin sensitivity and ovarian function. - Alpha-lactalbumin is a major whey protein in mammalian milk that not only serves as a nutrient but also aids intestinal absorption of myo-inositol, increases its plasma bioavailability, and may exert anti-inflammatory effects by inhibiting cyclooxygenase-2 (COX2) and decreasing IL-6 levels[4][5]. - In clinical studies, the combination was shown to restore ovulation in myo-inositol-resistant PCOS patients and reduce the need for insulin treatment and pre-term birth rates in GDM[1][3][4][5]. - The combination may also modulate gut microbiota, enhancing myo-inositol absorption[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inositol + alpha-lactalbumin.